• Affimed, Roche Explore AFM24, Tecentriq Combo contractpharma
    February 04, 2021
    Affimed N.V., a clinical-stage immuno-oncology company, entered a clinical research collaboration with Roche to explore the combination of Affimed’s innate cell engager (ICE) AFM24 with Roche’s PD-L1 checkpoint inhibitor atezolizumab (Tecentriq).
PharmaSources Customer Service